Patient Care An Iraqi boy from Mosul went from Jordan to Australia for surgery to correct the blood flow through his heart and repair a hole between his ventricles.
This site is not optimized for Internet Explorer 8 (or older).
Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.
August 4, 2017
August 2, 2017
Frailty is an important factor in patients undergoing either Transcatheter or Surgical Aortic Valve Replacement. However, it is hard to assess. Multiple scoring systems have been proposed which are either underperforming or are cumbersome to calculate.
July 18, 2017
In this large propensity-matched study, outcomes after Transcatheter versus Surgical Aortic Valve Replacement (TAVR vs. SAVR) were assessed in a real world intermediate- and high-risk cohort of 9500 patients in the United States. There was no difference in 1-year mortality (17.3% vs.
July 14, 2017
May 27, 2017
A statewide quality initiative database that included over 11,500 pts undergoing surgical AVR (SAVR) who were assessed for outcomes based on pre-TAVR and post-TAVR time periods (divided into early TAVR and commercial TAVR). SAVR rates increased with each time period, wheres predicted mortality rates decreased, observed mortality was lowest during th
Transcatheter Aortic Valve Replacement Outcomes in Nonagenarians Stratified by Transfemoral and Transapical Approach
May 27, 2017
Data from the Centers for Medicare and Medicaid Services related to patients aged 65 and older who underwent TAVR during a 2 year period were evaluated, stratified into older (age 90 or greater; 19.3%) and younger cohorts. Nonagenarians had fewer comorbidities. Mortality was higher in nonagenarians (8.4% vs 5.9%) as was morbidity (25.4% vs 21.5%).
One-Year Outcomes of Transcatheter Aortic Valve Replacement in Patients With End-Stage Renal Disease
May 17, 2017
Using data from the CoreValve US Expanding Use Study, outcomes for patients with end stage renal disease (ESRD) undergoing TAVR were evaluated using an endpoint of all-cause mortality or major stoke at 1 year. Mortality at 1 year was 30%, and the stroke incidence was 2.1%. New permanent pacemaker need was 27%.
May 14, 2017
Bicuspid aortic valve (BAV) has been considered a relative contraindication for transcatheter aortic valve implantation (TAVI). Nevertheless, favourable results have been reported from registries and observational reports.
Differences in left ventricular remodelling in patients with aortic stenosis treated with transcatheter aortic valve replacement with corevalve prostheses compared to surgery with porcine or bovine biological prostheses.
February 13, 2017
The authors report on an echocardiographic sub-study of the NOTION trial, a prospective randomized study which compared outcomes between 120 patients undergoing TAVI and 112 patients undergoing aortic valve replacement (AVR).
Incidence, Predictors, and Mid-Term Outcomes of Percutaneous Closure Failure After Transfemoral Aortic Valve Implantation Using an Expandable Sheath (from the Optimized Transcatheter Valvular Intervention [OCEAN-TAVI] Registry)
December 27, 2016
The authors report on their findings an ongoing Japanese multicentre prospective registry. They evaluate outcomes in 478 patients undergoing transfemoral TAVI and treated with percutaneous puncture using an expandable sheath, Edwards Sapien XTprosthesis and a Perclose ProGlide system.